2 citations
,
May 2008 in “Journal of Clinical Oncology” AZD6244 treatment causes skin aging effects by depleting skin stem cells.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
Cialis and Finasteride could be repurposed to treat aggressive melanoma.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
21 citations
,
February 2013 in “Clinics in Dermatology” New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
November 2023 in “Dermatology and Therapy” Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.
18 citations
,
October 2010 in “Bioorganic & Medicinal Chemistry Letters” New hybrid compound found to effectively prevent hair loss.
Ribonucleotide excision repair is crucial to prevent skin cancer.
March 2025 in “Jurnal Farmamedika (Pharmamedica Journal)” Procyanidin from Indonesian spices may help heal diabetic wounds.
January 2024 in “Case Reports in Dermatological Medicine” Baricitinib may effectively treat nail changes in alopecia areata.
September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
4 citations
,
September 2017 in “Dermatologic surgery” The combination therapy improved skin pigmentation.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
3 citations
,
May 2019 in “Journal of Cosmetic Dermatology” Pro-Ile could be used in cosmetics to improve skin, hair growth, and healing.
1 citations
,
October 2024 in “JAAD Case Reports” Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
1 citations
,
August 2025 Drug repurposing can speed up and reduce costs in drug discovery, especially for cancer treatment.
19 citations
,
January 2012 in “Dermatology” Topical human epidermal growth factor may effectively treat acne caused by cancer medication.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
March 2025 in “FEBS Journal” Epiprofin suppresses parathyroid hormone gene activity, helping regulate calcium levels and could be a treatment target for hyperparathyroidism.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology”
February 2024 in “Experimental Dermatology” IGFBP-rP1 could be a new treatment for a common type of hair loss.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.